Doxorubicin, Paclitaxel and Gemcitabine: a Phase I Study of a New Sequential Treatment in Stage III B - IV Breast Cancer

REFERENCES

• Nabholtz JM, Lindsay MA, Hugh J et al. The academic global virtual concept in clinical cancer research and its appli-cation to breast cancer: the Breast Cancer International Research Group. Semin Oncol 1999; 26 (3 Suppl 8): 4-8.
   Google Scholar
• Michael M, Bishop JF, Levi JA et al. Australian multi-centre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy. Med J Aust 1997; 166 (10): 530–533.
   Google Scholar
• Gianni L, Munzone E, Capri G et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infu-sion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87 (15): 1169-1175.
   Google Scholar
• Smith RE, Brown AM, Mamounas EP et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999; 17 (11): 3403-3411.
   Google Scholar
• ten Bokkel Huinink WW, Prove AM, Piccart M et al. A Phase II trial with docetaxel (Taxotere) in second line treat-ment with chemotherapy for advanced breast cancer. A study of the EORTC-ECTG. Ann Oncol 1994; 5 (6): 527–532.
   Google Scholar
• Ferraresi V, Milella M, Vaccaro A et al. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. Am J Clin Oncol 2000; 23 (2): 132–139.
   Google Scholar
• Bonneterre J, Spielman M, Guastalla JP et al. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 1999; 35 (10): 1431–1439.
   Google Scholar
• Burris HA 3rd. Single-Agent Docetaxel (Taxotere) in randomized phase III trials. Semin Oncol 1999; 26 (3 Suppl 9): 1-6.
   Google Scholar
• Di Leo A, Piccart MJ. Paclitaxel activity, dose and schedule: data from phase III trials in metastatic breast cancer. Semin Oncol 1999; 26 (3 Suppl 8): 27-32.
   Google Scholar
• Sledge GW, Neuberg D, Ingle J, Martino S, Wood W. Phase III trial of doxorubicin (A) vs. paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Am Soc Clin Oncol 1997; 16: la (Abstr).
   Google Scholar
• Chan S, Friedrichs K, Noel D et al. Prospective ran-domized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17 (8): 2341–2354.
   Google Scholar
• Jacobs SA, Stoller RG, Earle MF, Seid JE, Evans TL, Oriss CA. Phase I study of sequential adriamycin and Taxol with neupogen support in advanced breast cancer. Proc Am Soc Clin Oncol 1996; 15: 97 (Abstr).
   Google Scholar
• Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor effica-cy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13 (11): 2688-2689.
   Google Scholar
• Holmes FA, Madden T, Newman RA et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by pacli-taxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996; 14 (10): 2713–2721.
   Google Scholar
• Sledge GW, Robert B, Sparano JA et al. Paclitaxel/doxorubicin combinations in advanced breast can-cer: the ECOG experience. Semin Oncol 1994; 21 (5 Suppl. 8): 15-18.
   Google Scholar
• Fisherman JS, Cowan KH, Noone M et al. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony stimulating factor in patients with metastat-ic breast cancer. J Clin Oncol 1996; 14 (3): 774-782.
   Google Scholar
• Frassineti GL, Zoli W, Silvestro L et al. Paclitaxel plus doxorubicin in breast cancer: an Italian experience. Semin Oncol 1997; 24 (5 Suppl 17): 17-25.
   Google Scholar
• Zoli W, Ricotti L, Barzanti F et al. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 1999; 80 (3): 413–416.
   Google Scholar
• Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53 (5): 1037–1042.
   PubMed Web of Science ®Google Scholar
• Abbruzzese JL, Grunewald R, Weeks EA et al: A phase I clinical, plasma, and cellular pharmacology study of gemc-itabine. J Clin Oncol 1991; 9 (3): 491–498.
   PubMed Web of Science ®Google Scholar
• Camaggi CM, Strocchi E, Tamassia V et al: Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases. Cancer Treat Rep 1982; 66 (10): 1819–1824.
   PubMedGoogle Scholar
• American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimu-lating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12 (11): 2471-2508.
   Google Scholar
• Jassem J, Pienkowski T, Pluzanska A et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized Phase III multicenter trial. J Clin Oncol 2001; 19 (6): 1707–1715.
   Google Scholar
• Amadori D, Frassineti GL, Zoli W et al. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Semin Oncol 1996; 23 (5 Suppl 11): 16-22.
   Google Scholar